Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma-Reference-Cited by-同舟云学术

Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma

Published:2010-04-28 Issue:5 Volume:78B Page:338-347
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Johnsen Hans E.,Bøgsted Martin,Klausen Tobias W.,Gimsing Peter,Schmitz Alexander,Kjaersgaard Erik,Damgaard Tina,Voss Pia,Knudsen Lene M.,Mylin Anne K.,Nielsen Johan Lanng,Björkstrand Bo,Gruber Astrid,Lenhoff Stig,Remes Kari,Dahl Inger Marie,Fogd Kirsten,Dybkaer Karen

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Reference79 articles.

1. Flow cytometric immunophenotyping for hematologic neoplasms;Craig;Blood,2008

2. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smouldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells;Perez-Persona;Blood,2007

3. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma;Lin;Am J Clin Pathol,2004

4. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome;San Miguel;Blood,2002

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis;JCI Insight;2022-10-24

2. Issue Highlights—July 2022;Cytometry Part B: Clinical Cytometry;2022-07

3. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial;BMC Cancer;2022-02-05

4. The Prognostic Value of Immunophenotypic Characteristics of Plasma Cells in Newly Diagnosed Multiple Myeloma Patients Treated with First-Generation Proteasome Inhibitor Bortezomib;Clinical oncohematology;2022

5. CD5+ B lymphoproliferative disorder with subsequent development of plasma cell leukaemia: Diagnostic and aetiologic reasoning;Cytometry Part B: Clinical Cytometry;2017-11-02